Sirtuin 1: A Dilemma in Transplantation

Table 2

Sirtuin 1 effects on stem cells and liver transplantation.

Stem cell transplantation

Sirt1−/− bone marrow TX ⟶ normal output (55); Sirt1−/− bone marrow TX ⟶ stem cells aberrant expansion, increased DNA damage, p53 overactivation, and genomic instability (56); Intrabone marrow-bone marrow TX ⟶ amelioration of SAMP10 and mice nonalcoholic fatty liver disease (57, 58); SRT-1720-pretreated-mesenchymal stem cells infusion to myocardial infarction model ⟶ left ventricular ejection fraction↑, angiogenesis↑, fibrosis↓(59); Sirt1-KO skeletal stem cell TX infusion to myocardial infarction model ⟶ functional improvement↓, proliferation rate↓, cytokine secretion↑(60)

Liver transplantation

Liver preservation in TMZ ⟶ Sirt1 activation ⟶ p53 and FoxO expression↓, ALT and GDH↓, improved graft survival (61); Losartan administration before liver TX ⟶ Sirt1↑, FoxO1↓, ALT and AST↓, caspase 12 and cleaved caspase 3↓(62)

Sirt1: sirtuin 1; TX: transplantation; SAMP10: senescence-accelerated mice prone 10; TMZ: trimetazidine; ALT: alanine aminotransferase; AST: aspartate aminotransferase; GDH: glutamate dehydrogenase.